Research for the last few years in our laboratory has revealed that one of the physiological functions of APP is to regulate cellular functions and survival. In particular, APP has been found to be a trophic molecule that regulates neurite extension in vitro and synaptic formation/structure in vivo. Considering that in many instances trophic factors protect neurons from damages caused by various injuries, APP is a prominent candidate for the intervention of neuronal injuries. Therefore, we propose to study the involvement of APP in several models of neuronal and synaptic degeneration and regeneration.
In Specific Aim 1, we will determine the degree of APP involvement in the rabbit spinal cord ischemia model (RSCIM). Our hypothesis is that APP synthesis and degradation are affected by ischemia as a part of the protective mechanisms to counteract the damage induced by ischemia. APP isoforms before and after ischemia will be quantified and localized, where possible, at both protein and mRNA levels using various techniques including Western blotting, immunohistochemistry, Northern blotting, slot blotting, RT-PCR technique, and in situ hybridization. This work serves as a foundation for Specific Aim 2 where we will optimize the procedure for the APP-peptide therapy using RSCIM. This study is based on our recent finding that a short peptide fragment representing the active trophic domain of APP antagonizes the ischemia-induced damage in rabbit spinal cords. We will evaluate ischemic injury using clinical, biochemical, molecular biological, and morphological criteria. Morphological criteria include neuronal and synaptic counts.
In Specific Aim 3, we will examine a potential APP involvement in the sprouting reactions in the molecular layer of the dentate gyrus after the perforant path (PP) lesion. We will ask which neurons produce APP in response to PP lesion, and also if the infusion of a peptide which interferes with the function of APP inhibits the sprouting.
Specific Aim 4 will test the hypothesis that the effect of NGF and beta-FGF to rescue medioseptal neurons from degeneration after the transection of fimbria-fornix (FF) is partially through the activation of putative APP pathways. We will investigate the effect of APP peptide infusion on the medioseptal neurons after FF lesion. Then, we will attempt to antagonize the effects of NGF and bFGF by co-infusing a peptide that completes with APP and blocks its function. Finally, in Specific Aim 5, we will test the potential effect of APP agonists and antagonists in the protection by growth factors from glutamate-induced neuronal toxicity employing the in vitro culture model.

Project Start
1997-06-01
Project End
1998-05-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
7
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Maher, Pamela (2014) Proteasome Assay in Cell Lysates. Bio Protoc 4:
Brennand, K J; Simone, A; Tran, N et al. (2012) Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 17:1239-53
Brennand, Kristen J; Simone, Anthony; Jou, Jessica et al. (2011) Modelling schizophrenia using human induced pluripotent stem cells. Nature 473:221-5
Brennand, Kristen J; Gage, Fred H (2011) Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells 29:1915-22
Maher, Pamela (2008) Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism. Biochem Pharmacol 75:1994-2006
Maher, Pamela (2008) The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity. Arch Biochem Biophys 476:139-44
Maher, Pamela; Salgado, Karmen F; Zivin, Justin A et al. (2007) A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173:117-25
Shackelford, Deborah A (2006) DNA end joining activity is reduced in Alzheimer's disease. Neurobiol Aging 27:596-605
Lapchak, Paul A (2006) Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res 1088:141-7
Lapchak, Paul A (2006) 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp Neurol 197:531-7

Showing the most recent 10 out of 142 publications